Cochrane · systematic review · CD012035
Thrombopoietin receptor agonists for prevention and treatment of chemotherapy‐induced thrombocytopenia in patients with solid tumours
Zhang, X, Chuai, Y, Nie, W, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
HaematologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
5
No studies
9
Included studies
NR
No studies 9 · 64.3%Ungraded 0 · 0%Very low 4 · 28.6%Low 1 · 7.1%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Comparison
Population: patients with solid tumours without thrombocytopenia before chemotherapy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality | RR 1.35 [0.53, 3.45] | 1 study · 26 participants | Low Downgraded: imprecision |
Number of patients with at least one bleeding episode of any severity | RR 0.62 [0.22, 1.78] | 2 studies · 206 participants | Very low Downgraded: risk of bias, imprecision |
Number of patients with at least one severe/life‐threatening bleeding episode | RR 0.36 [0.06, 2.06] | 2 studies · 206 participants | Very low Downgraded: risk of bias, imprecision |
Number of treatment cycles with at least one bleeding episode ‐ not measured | no estimate extracted | NR | No studies |
Number of days on which bleeding occurred ‐ not measured | no estimate extracted | NR | No studies |
The amount of bleeding ‐ not measured | no estimate extracted | NR | No studies |
Quality of life score ‐ not measured | no estimate extracted | NR | No studies |
Comparison
Population: patients with solid tumours with thrombocytopenia during chemotherapy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival ‐ not measured | no estimate extracted | NR | No studies |
Number of patients with at least one bleeding episode of any severity | RR 2.8 [0.17, 47.53] | 1 study · 62 participants | Very low Downgraded: risk of bias |
Number of patients with at least one severe/life‐threatening bleeding episode | no estimate extracted | 1 study · 62 participants | Very low Downgraded: risk of bias |
Number of treatment cycles with at least one bleeding episode ‐ not measured | no estimate extracted | NR | No studies |
Number of days on which bleeding occurred ‐ not measured | no estimate extracted | NR | No studies |
The amount of bleeding ‐ not measured | no estimate extracted | NR | No studies |
Quality of life score ‐ not measured | no estimate extracted | NR | No studies |